拉考沙胺与左乙拉西坦单药治疗成人癫痫的骨折风险比较
本研究为回顾性队列研究,利用TriNetX全球协作网络纳入成人癫痫起始拉考沙胺或左乙拉西坦单药治疗者,经倾向评分1:1匹配后每组20,888例。5年随访显示拉考沙胺组复合骨折发生率为2.86%,左乙拉西坦组为2.09%(HR 1.27;95%CI 1.11-1.44;p<0.001)。结论提示拉考沙胺单药治疗与更高的骨折风险相关。
要点
- 拉考沙胺单药治疗5年复合骨折风险高于左乙拉西坦(HR 1.27)。
- 前臂骨折、主要骨质疏松性骨折及新发骨质疏松风险均升高。
- 骨骼脆性高的癫痫患者选择抗癫痫发作药物时应考虑此差异。
核心结论
- 成人癫痫患者中,拉考沙胺单药治疗与左乙拉西坦相比5年骨折风险显著更高。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络数据,纳入起始拉考沙胺或左乙拉西坦单药治疗的成人癫痫患者,排除联用其他抗癫痫发作药物者。
- 经倾向评分1:1匹配平衡人口学、合并症和用药后,每组20,888例,随访5年。
主要发现
- 复合骨折(髋部、颈椎、前臂)在拉考沙胺组发生574例(2.86%),左乙拉西坦组418例(2.09%)(HR 1.27;95%CI 1.11-1.44;p<0.001)。
- 前臂骨折风险升高(HR 1.33;p=0.01)。
- 主要骨质疏松性骨折风险升高(HR 1.21;p<0.001)。
- 新发骨质疏松风险升高(HR 1.18;p<0.001)。
- 要求≥6次处方续配并排除其他新型抗癫痫发作药物的敏感性分析保留了效应方向。
关键数值与推荐
- 复合骨折5年风险:拉考沙胺2.86% vs 左乙拉西坦2.09%(HR 1.27;95%CI 1.11-1.44;p<0.001)。
- 前臂骨折HR 1.33(p=0.01);主要骨质疏松性骨折HR 1.21(p<0.001);新发骨质疏松HR 1.18(p<0.001)。
- 证据等级:Class III,提示成人癫痫单药治疗中拉考沙胺与更高的5年骨折风险相关。
临床怎么用
- 对于骨骼脆性升高的癫痫患者,选择抗癫痫发作药物时应权衡拉考沙胺与左乙拉西坦的骨折风险差异。
- 使用拉考沙胺单药治疗的患者可考虑评估骨折风险并加强骨骼健康监测。
局限性
- 存在残余混杂。
- 回顾性设计无法进行因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with epilepsy exhibit substantially elevated fracture risk. However, comparative skeletal safety data for newer antiseizure medications (ASMs) remain limited. The aim of this study was to compare fracture risk between lacosamide and levetiracetam monotherapy in adults with epilepsy. METHODS: This retrospective cohort study used the TriNetX Global Collaborative Network. Adults with epilepsy initiating lacosamide or levetiracetam monotherapy were identified, excluding those receiving concomitant ASMs. Propensity score matching (1:1) balanced cohorts on demographics, comorbidities, and medications. The primary outcome was composite fracture (hip, cervical vertebra, and forearm). Cox regression estimated hazard ratios (HR) over 5-year follow-up. A sensitivity analysis requiring ≥6 prescription fills and excluding additional newer generation ASMs was performed. RESULTS: After matching, 20,888 patients remained per cohort with balanced covariates. Composite fracture occurred in 574 (2.86%) lacosamide-treated vs 418 (2.09%) levetiracetam-treated patients (HR 1.27; 95% CI 1.11-1.44; p < 0.001). Elevated risk was observed for forearm fracture (HR 1.33; p = 0.01), major osteoporotic fracture (HR 1.21; p < 0.001), and incident osteoporosis (HR 1.18; p < 0.001). Sensitivity analysis with stricter monotherapy and longer exposure preserved the direction of effect. DISCUSSION: Lacosamide monotherapy was associated with significantly higher fracture risk compared with levetiracetam. These findings should inform ASM selection in patients with elevated skeletal fragility. Limitations include residual confounding and the retrospective design that precludes causal inferences. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that among adults with epilepsy receiving monotherapy, lacosamide is associated with a higher 5-year risk of fracture than levetiracetam.
引用
- AbuAlrob MA, Al-Salahat A, Abdellatif R, et al. Fracture Risk With Lacosamide vs Levetiracetam Monotherapy in Adults With Epilepsy. Neurology. 2026. PMID: 42475648. doi:10.1212/WNL.0000000000218269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。